Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Content Channel
Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF
If successful, ivonescimab would be the first regimen to show a survival benefit over a PD-1/chemotherapy combo in first-line NSCLC in a phase 3 trial.
Angus Liu
May 27, 2026 11:25am
ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS
May 21, 2026 5:00pm
Summit shares tumble on interim PD-1/VEGF trial miss
May 1, 2026 10:56am
Takeda, GLP-1 generics, Gilead—Fierce Pharma Asia
Mar 27, 2026 8:38am
Dizal's Zegfrovy adds more pressure to J&J's Rybrevant
Mar 23, 2026 10:25am
Novo's Indiana plant claims another victim in Incyte's PD-1
Mar 9, 2026 10:45am
